NasdaqGM:PAHCPharmaceuticals
Assessing Phibro Animal Health (PAHC) Valuation After Strong Q2 Results And Higher 2026 Earnings Guidance
Phibro Animal Health (PAHC) is back in focus after reporting second quarter results that show much higher sales and net income versus a year earlier, along with updated 2026 earnings guidance and a reaffirmed dividend.
See our latest analysis for Phibro Animal Health.
The recent guidance update and stronger quarterly results have come after a sharp run in the shares, with a 30 day share price return of 31.47% and a year to date share price return of 39.01%. Longer term momentum is reflected...